An Observational Study of the Effect of Levodopa–Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients

被引:0
作者
Rejko Krüger
Paul Lingor
Triantafyllos Doskas
Johanna M. L. Henselmans
Erik H. Danielsen
Oriol de Fabregues
Alessandro Stefani
Sven-Christian Sensken
Juan Carlos Parra
Koray Onuk
Ashley Yegin
Angelo Antonini
机构
[1] University of Luxembourg,Luxembourg Center for Systems Biomedicine
[2] Centre Hospitalier de Luxembourg,Center for Neurology
[3] University of Tübingen,Department of Neurology
[4] University Medical Center Göttingen,Department of Neurology, Vall d’Hebron University Hospital, Neurodegenerative Diseases Group, Vall d’Hebron Research Institute
[5] Naval Hospital of Athens,Parkinson Center, Department System Medicine
[6] Antonius Hospital Woerden and Leiden University Medical Center,Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua
[7] Aarhus University Hospital,undefined
[8] Autonomous University of Barcelona,undefined
[9] Fondazione Policlinico Tor Vergata,undefined
[10] AbbVie Deutschland GmbH & Co KG,undefined
[11] AbbVie Inc,undefined
[12] IRCCS Hospital San Camillo,undefined
来源
Advances in Therapy | 2017年 / 34卷
关键词
Activities of daily living; Levodopa–carbidopa intestinal gel; Parkinson’s disease; Percutaneous endoscopic gastrojejunostomy; Quality of life;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1741 / 1752
页数:11
相关论文
共 105 条
[1]  
Ahlskog JE(2001)Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 448-458
[2]  
Muenter MD(2001)Gastric emptying time and gastric motility in patients with Parkinson’s disease Mov Disord 16 1041-1047
[3]  
Hardoff R(2010)Pharmacokinetics of levodopa J Neurol 257 S253-S261
[4]  
Sula M(2007)Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients Mov Disord 22 1623-1629
[5]  
Tamir A(2012)The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life J Neurol 259 2621-2631
[6]  
Contin M(2009)Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life Mov Disord 24 1468-1474
[7]  
Martinelli P(2016)Non-motor symptoms and quality of life in patients with Parkinson’s disease in Northeastern Mexico Acta Neurol Belg 116 157-161
[8]  
Martinez-Martin P(2013)Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson’s disease J Neurol Sci 332 136-140
[9]  
Schapira AH(2015)Jejunal infusion of levodopa–carbidopa intestinal gel versus oral administration of levodopa–carbidopa tablets in Japanese subjects with advanced Parkinson’s disease: pharmacokinetics and pilot efficacy and safety Clin Pharmacokinet 54 975-984
[10]  
Stocchi F(2014)Continuous intrajejunal infusion of levodopa–carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study Lancet Neurol 13 141-149